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Ornithine transcarbamylase (OTC) deficiency is well known for its diagnosis in the neonatal period. Presentation often occurs after
protein feeding and manifests as poor oral intake, vomiting, lethargy progressing to seizure, respiratory difficulty, and eventually
coma. Presentation at adulthood is rare (and likely underdiagnosed); however, OTC deficiency can be life-threatening and requires
prompt investigation and treatment. Reports and guidelines are scarce due to its rarity. Here, we present a 59-year-old womanwith a
past history of irritable bowel syndromewho underwent a reparative operation for rectal prolapse and enterocele. Her postoperative
course was complicated by a bowel perforation (which was repaired), prolonged mechanical ventilation, tracheostomy, critical
illness myopathy, protein-caloric malnutrition, and altered mental status. After standard therapy for delirium failed, further
investigation showed hyperammonemia and increased urine orotic acid, ultimately leading to the diagnosis of OTC deficiency.This
case highlights the importance of considering OTC deficiency in hospitalized adults, especially during the diagnostic evaluation
for altered mental status.
1. Introduction
Ornithine transcarbamylase (OTC) deficiency (also referred
to as ornithine carbamoyltransferase deficiency) is an X-
linked proximal urea cycle disorder that results in a spectrum
of severe neonatal-onset disease in boys, rarely in girls, and
a milder adult-onset presentation. In the urea cycle, OTC
combines ornithine and carbamoyl phosphate to form cit-
rulline. Thus, an OTC enzyme deficiency leads to decreased
production of citrulline, interruption of the urea cycle,
increased orotic acid which is produced by excess carbamoyl
phosphate, and ultimately life-threatening hyperammonemia
due to the inability to excrete excess nitrogen. In females,
the severity of the condition depends on the amount of X-
inactivation of the pathogenic OTC allele and resultant OTC
enzyme activity in the liver [1].
OTC deficiency can range from asymptomatic to severely
symptomatic in heterozygous adults; those with a milder
disease course often report a history of self-limiting protein
intake. Acute hyperammonemic episodes can occur and are
often triggered by major illness, surgery, pregnancy, corticos-
teroid and valproic acid administration, prolonged fasting,
increased protein intake, and total parenteral nutrition (TPN)
[2–6].
These hyperammonemic episodes present with neuro-
logic abnormalities such as encephalopathy, psychosis, and
delirium, which can progress to coma and death. Although
limited, some reports describe the severity of this disease
and emphasize the risk of death if undiagnosed. Brassier et
al. [1] reviewed the long-term outcomes of 90 patients with
OTC deficiency: 70% presented after the neonatal period and
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9% of the late onset group (>1 month of age) died on initial
presentation. Batshaw et al. [7] analyzed a larger group of
patients (𝑛 = 614), and 66% of patients presented after the
neonatal period; the overall mortality rate in the late onset
age group was 11%.
2. Case Presentation
A 59-year-old woman with a history of irritable bowel
syndrome and protein aversion, which led to a preferential
vegetarian diet, was admitted for elective reparative surgery
to treat rectal prolapse and enterocele. Her postoperative
course was complicated by bowel perforation (requiring
small bowel resection and end ileostomy), fecal peritonitis,
intra-abdominal abscesses, septic shock, respiratory failure,
tracheostomy, critical illness myopathy, protein-caloric mal-
nutrition, and altered mental status (AMS). The patient
provided written informed consent to publish these findings.
The patient’s daily spontaneous awakening trials during
her intensive care unit (ICU) course showed a positive
evaluation on the Confusion Assessment Method for the
ICU, score of +3 on the Richmond Agitation and Sedation
Scale, and inability to follow 2-step commands, which led
to an initial diagnosis of delirium. After standard delir-
ium treatment was unsuccessful, further ICU investigation
yielded normal renal, thyroid, and liver function. However,
she had a markedly elevated ammonia level (100mcmol/L,
normal 0–30). Noncontrast head computed tomography and
magnetic resonance imaging of the brain were negative for
acute intracranial process.
Electroencephalography showed no evidence of non-
convulsive status epilepticus. Urine orotic acid and plasma
amino acid panel were ordered to investigate her unexplained
hyperammonemia. Her urine orotic acid level was elevated
(3.2mmol/mol creatinine, normal 0.4–1.2) but the plasma
glutamine (normal 371–957 nmol/ml), ornithine (normal
38–130 nmol/ml), citrulline (normal 17–46 nmol/ml), argi-
nine (normal 30–120 nmol/ml), and argininosuccinic acid
(normal <2 nmol/ml) were within normal ranges. Nitrogen
scavengers were not initiated at this time since there were no
abnormalities in the rest of the urea cycle panel, ammonia
began to trend down, and her mental status subsequently
improved.
Because of prolonged mechanical ventilation and wean-
ing failure, the patient received a standard polymeric enteral
formula with a modular protein supplement. This was tran-
sitioned to an isotonic enteral formula after her ileostomy
output increased. Her enteral nutrition was inconsistent dur-
ing her ICU stay because of intestinal perforation, multiple
planned procedures, intermittent high doses of vasopressors,
and fluctuating doses of propofol.
On day 25 in the hospital, she was transferred to the step-
down unit at her baselinemental state. Her appetite remained
poor as she continued to experience bloating, nausea, and
high gastric residual volume resulting in intermittent enteral
and oral feeding. Trials of antiemetics, appetite stimulants,
nutrition supplements, and diet adjustments were unsuccess-
ful.
In the days approaching discharge, she had acute
neurologic changes overnight, including visual hallucina-
tions, hyperreflexia, clonus, generalized high-frequency low-
amplitude tremors, nystagmus, and delirium. During the
same night, she received the longest period of continuous
enteral feeding since admission.
After this sudden neurologic decline on the step-down
unit, OTC deficiency as a diagnosis was investigated further
and empiric treatment was immediately initiated. Urine
organic acid and acylglycines, quantitative plasma amino
acid, and quantitative plasma acylcarnitine panels were
ordered to screen for inborn errors of metabolism.This addi-
tional testing confirmed increased orotic acid, low citrulline,
and elevated ammonia levels. The constellation of elevated
urine orotic acid, low citrulline, persistent hyperammonemia
with normal liver function, ketonuria, feeding difficulty,
and neurologic changes were so highly suspicious of OTC
deficiency; a confirmation of diagnosis by means of liver
biopsy was not performed.
3. Treatment
This patient’s management was based on consultation with a
biochemical geneticist and focused on 4 main areas: restric-
tion of protein, promotion of anabolism, administration of
nitrogen-scavenging medications, and monitoring. Protein
intake was withheld for 24 hours at treatment onset and then
limited to 0.5 g/kg per day with a calorie goal of 30 kcal/kg. In
this case, protein restriction could not be achieved through
the available enteral formulas in the inpatient setting. TPN
was initiated with dextrose (100 g), a lipid emulsion (28 g),
and standard essential amino acids (25 g). Rohr recommends
30% to 50% of total protein be given as essential amino acids,
a provision that is important for preventing chronic protein
insufficiency [8].
To stimulate the urea cycle, intravenous arginine was
initiated at a continuous rate of 600mg/kg per day, alongwith
10% dextrose in normal saline at 125 cc/hr [6]. A glucose goal
of 100 to 150mg/dL was maintained with an insulin drip.
Ammonia scavenger therapy with intravenous sodium
benzoate and sodium phenylacetate was initiated. Hemodial-
ysis can be used for refractory hyperammonemia, but this
intervention was not needed by our patient [6].While receiv-
ing these interventions, her serum sodium and ammonia
levels were monitored every 4 hours and her serum amino
acid levels were monitored every 48 hours.
This course was continued until she became neuro-
logically stable, at which time her oral discharge regimen
was initiated. This regimen included a specially ordered,
protein-free infant formula mixed with almond milk. She
was instructed to consume 3 portions of this supplement
daily, with a protein intake goal of less than 25 g per day.
She received nutritional education regarding the effects of
protein in patients with OTC deficiency and the importance
of protein restriction. She was discharged with oral arginine
(500mg, 3 times per day). On follow-up, she was transitioned
to oral citrulline (1.3 g, 3 times per day) (3 g/m2) and sodium
phenylbutyrate (4.5 g, 3 times per day) (10 g/m2).
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Table 1: Differential diagnosis of altered mental status.
Origin of AMS Differential diagnosis
Infection Urinary tract infection, pneumonia, bacteremia, meningitis, encephalitis, brain abscess,neurosyphilis, fever
Withdrawal Alcohol, sedative-hypnotic drugs, barbiturates, benzodiazepines
Acute metabolic condition Acid-base disturbance, electrolyte imbalance, liver or renal failure
Trauma Head injury, surgery, burns, heat stroke, hypothermia
Central nervous system
pathology
Subdural hematoma, epidural hematoma, subarachnoid hemorrhage, hydrocephalus, seizure, stroke,
tumor, demyelinating lesion, transient ischemic attack
Hypoxia or cardiopulmonary
condition
Hypoxemia, hypotension or shock, arrhythmia, anemia, carbon monoxide poisoning,
methemoglobinemia
Vitamin deficiency Thiamine (Wernicke encephalopathy), niacin, vitamin B12
Endocrinopathy Hyperadrenocorticism, hypoadrenocorticism, hyperglycemia, hypoglycemia, hyperthyroidism,hypothyroidism, hypercalcemia
Acute vascular condition Hypertensive encephalopathy, stroke, arrhythmia, shock, thrombotic thrombocytopenic purpura,mesenteric ischemia
Toxin or drug toxicity Sedatives, narcotics, anticholinergics, antipsychotics, neuroleptic malignant syndrome, serotoninsyndrome, illicit drugs
Heavy metal poisoning Lead, arsenic, manganese, mercury, thallium
4. Outcome and Follow-Up
After prompt initiation of OTC specific treatment including
nitrogen scavengers and restricted protein, her neurologic
symptoms improved over 48 hours, and by 72 hours, she had
returned to her baseline mental and neurologic state. Her
inpatient oral intake adequately met goals, and TPN was dis-
continued. Shewas transitioned to a short-term rehabilitation
facility, and on discharge to home, she was eating a regular-
texture oral diet and supplementing with low-protein for-
mula. Unfortunately, this diet was not sustained over several
weeks, and she had failure to thrive. Shewas readmitted to the
hospital for reinitiation of TPN in addition to oral diet. Upon
final discharge, outpatient follow-up included consultations
with a geneticist and genetic dietician.
5. Discussion
This case depicts a unique diagnosis (OTC) to a common
clinical dilemma (AMS). The most common causes of AMS
are cerebrovascular, traumatic, metabolic, infectious, psychi-
atric, and endocrine in origin [9]. Table 1 includes the broad
range of disorders that can result in AMS.
OTC deficiency is not routinely considered during an
investigation of AMS; however, early diagnosis and treatment
are imperative to prevent severe neurologic injury and death
[6]. For our patient, OTC deficiency was considered in
the differential diagnosis because of her persistent hyper-
ammonemia and nutritional history (preferential vegetar-
ian diet) and the consistent failure of traditional delirium
therapies. This case exemplifies the important role of multi-
disciplinary collaboration and communication in managing
this uncommon deficiency in a urea cycle enzyme. During
this patient’s course, consultants from the departments of
intensive care, neurology, internal medicine, nutrition, and
genetics all had pivotal roles in diagnosing and treating this
patient’s disease.
Abbreviations
AMS: Altered mental status
ICU: Intensive care unit
OTC: Ornithine transcarbamylase
TPN: Total parenteral nutrition.
Conflicts of Interest
The authors declare that there are no conflicts of interest
regarding the publication of this article.
References
[1] A. Brassier, S. Gobin, J. B. Arnoux et al., “Long-term outcomes
in Ornithine Transcarbamylase deficiency: A series of 90
patients,”Orphanet Journal of Rare Diseases, vol. 10, no. 1, article
no. 58, 2015.
[2] M. A. Chiong, B. H. Bennetts, S. I. Strasser, and B. Wilcken,
“Fatal late-onset ornithine transcarbamylase deficiency after
coronary artery bypass surgery,” Medical Journal of Australia,
vol. 186, no. 8, pp. 418-419, 2007.
[3] W. T. Hu, O. H. Kantarci, J. L. Merritt II et al., “Ornithine tran-
scarbamylase deficiency presenting as encephalopathy during
adulthood following bariatric surgery,” JAMA Neurology, vol.
64, no. 1, pp. 126–128, 2007.
[4] S. Lipskind, S. Loanzon, E. Simi, and D. W. Ouyang, “Hyper-
ammonemic coma in an ornithine transcarbamylase mutation
carrier following antepartum corticosteroids,” Journal of Peri-
natology, vol. 31, no. 10, pp. 682–684, 2011.
[5] N. Marcus, O. Scheuerman, V. Hoffer, E. Zilbershot-Fink, J.
Reiter, and B. Z. Garty, “Stupor in an adolescent following
Yom Kippur fast, due to late-onset ornithine transcarbamylase
deficiency,” Israel Medical Association Journal, vol. 10, no. 5, pp.
395-396, 2008.
[6] J. Ha¨berle, N. Boddaert, A. Burlina et al., “Suggested guidelines
for the diagnosis and management of urea cycle disorders,”
Orphanet Journal of Rare Diseases, vol. 7, no. 1, article 32, 2012.
4 Case Reports in Critical Care
[7] M. L. Batshaw, M. Tuchman, M. Summar, and J. Seminara, “A
longitudinal study of urea cycle disorders,” Molecular Genetics
and Metabolism, vol. 113, no. 1-2, pp. 127–130, 2014.
[8] L. E. Bernstein, F. Rohr, and J. R. Helm, Nutrition Management
of Inherited Metabolic Diseases, Springer International Publish-
ing, Cham, 2015.
[9] S. T. Wilber, “Altered mental status in older emergency depart-
ment patients,” Emergency Medicine Clinics of North America,
vol. 24, no. 2, pp. 299–316, 2006.
Submit your manuscripts at
https://www.hindawi.com
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Behavioural 
Neurology
Endocrinology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Disease Markers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
PPAR Research
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
